Sugi Predict

Sugi Predict / Compounds / SCHEMBL16720552

SCHEMBL16720552

SCHEMBL16720552

COC(=O)c1cccc(Br)c1I

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.48
▸ LMNA P02545 1/20 0.48
▸ ALDH1A1 P00352 2/20 0.47
▸ HSD17B10 Q99714 2/20 0.47
▸ CFTR P13569 1/20 0.47
▸ SLC6A3 Q01959 1/20 0.46
▸ CA1 P00915 2/20 0.46
▸ CA2 P00918 2/20 0.46
▸ CA9 Q16790 2/20 0.46
▸ CA5A P35218 1/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ POLB P06746 1/20 0.46
▸ ATM Q13315 1/20 0.46
▸ SOS1 Q07889 1/20 0.45
▸ KMT2A Q03164 4/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ CYP1A2 P05177 2/20 0.44
▸ CYP2C19 P33261 2/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31719604 1.00 TSHR (0.48) TSHRLMNAALDH1A1HSD17B10CFTR
SCHEMBL2842204 0.86 TSHR (0.57) TSHRLMNAALDH1A1HSD17B10CFTR
SCHEMBL29279663 0.81 TSHR (0.52) TSHRLMNAALDH1A1HSD17B10CFTR
SCHEMBL26963002 0.81 KMT2A (0.44) ALDH1A1CA1CA2CA9KDM4E
SCHEMBL23659 0.80 TSHR (0.61) TSHRLMNAALDH1A1HSD17B10CFTR
SCHEMBL29433258 0.80 TSHR (0.61) TSHRLMNAALDH1A1HSD17B10CFTR
SCHEMBL23218849 0.79 TSHR (0.66) TSHRLMNAALDH1A1HSD17B10CFTR
SCHEMBL29852869 0.79 TSHR (0.66) TSHRLMNAALDH1A1HSD17B10CFTR
SCHEMBL28424016 0.79 TSHR (0.50) TSHRLMNAALDH1A1HSD17B10CFTR
SCHEMBL3161423 0.79 TSHR (0.50) TSHRLMNAALDH1A1HSD17B10CFTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12595239-B2 Substituted isoxazoline derivatives BASF SE (DE) 2026-04-07 — — US disclosed
EP-4291551-B1 SUBSTITUTED ISOXAZOLINE DERIVATIVES BASF SE (DE) 2025-08-13 — — EP disclosed
WO-2025106644-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ALPHA-V BETA-1 INTEGRIN MORPHIC THERAPEUTIC, INC. (US) 2025-05-22 — — WO disclosed
US-12258314-B2 EBNA1 inhibitors and their method of use THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2025-03-25 — — US disclosed
US-20250074864-A1 COMPOUNDS FOR ELECTRONIC DEVICES MERCK ELECTRONICS KGAA (DE) 2025-03-06 — — US disclosed
US-20250081842-A1 COMPOUNDS FOR ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2025-03-06 — — US disclosed
CN-114539287-B Polycyclic aromatic compound and application thereof in electroluminescent device 清华大学 2024-11-15 — — CN disclosed
EP-4423065-A1 COMPOUNDS FOR ELECTRONIC DEVICES Merck Patent GmbH (DE) 2024-09-04 — — EP disclosed
EP-4423063-A1 COMPOUNDS FOR ELECTRONIC DEVICES Merck Patent GmbH (DE) 2024-09-04 — — EP disclosed
WO-2024144186-A1 ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DIODE USING SAME 솔루스첨단소재 주식회사 2024-07-04 — — WO disclosed
CN-109415380-A Organic semiconductor compound 默克专利有限公司 2019-03-01 — — CN disclosed
CN-105980371-B Novel compound and organic light-emitting element comprising same 东进世美肯株式会社 2019-02-15 — — CN disclosed
CN-109328189-A Condensed dithienothiophene derivative is used as organic semi-conductor purposes with it 默克专利股份有限公司 2019-02-12 — — CN disclosed
CN-109305943-A One kind fluorene compound containing dibenzo and its organic luminescent device 长春海谱润斯科技有限公司 2019-02-05 — — CN disclosed
CN-105655496-B Organic luminescent compounds and organic electroluminescent device comprising it SFC株式会社 2018-11-23 — — CN disclosed
US-20180086699-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-03-29 — — US disclosed
US-9856214-B2 EBNA1 inhibitors and their method of use THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2018-01-02 — — US disclosed
US-20160289185-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-10-06 — — US disclosed
EP-3068758-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE The Wistar Institute Of Anatomy And Biology (US) 2016-09-21 — — EP disclosed
WO-2015073864-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE THE WISAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2015-05-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12258314-B2 EBNA1 inhibitors and their method of use EBNA1BP2, MLLT1, PML TSHR 4259/4885LMNA 649/4885ALDH1A1 3442/4885
US-12595239-B2 Substituted isoxazoline derivatives CBR3, ADRA2C, CYP4Z1 TSHR 1622/4885LMNA 1414/4885ALDH1A1 854/4885
US-20250081842-A1 COMPOUNDS FOR ELECTRONIC DEVICES CYP2C19, CYP2C9, ETV6 TSHR 4366/4885LMNA 3347/4885ALDH1A1 156/4885
US-20250074864-A1 COMPOUNDS FOR ELECTRONIC DEVICES CYP2C19, ETV6, CYP2C9 TSHR 3729/4885LMNA 3177/4885ALDH1A1 277/4885
US-20160289185-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE MCM5, EBNA1BP2, MLLT1 TSHR 4010/4885LMNA 560/4885ALDH1A1 4002/4885
US-20180086699-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE EBNA1BP2, MLLT1, PML TSHR 4259/4885LMNA 649/4885ALDH1A1 3442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.